12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Company News  |  Deals

Fibrocell, Intrexon deal

Fibrocell announced a deal to use synthetic biology technologies from Intrexon to develop and commercialize next-generation autologous fibroblast and dermal cell therapies. The deal includes...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >